Stemcell Holdings, Inc. Stocks

$ 0.06Last Updated 06.04.2026

Issuer Rating

Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 1.64M

Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0.06
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Stemcell Holdings, Inc., through its subsidiary, Stemcell Co., Ltd., engages in the regenerative medicine-related business. It provides technical assistance services to the culturing, storing, and delivery of stem cells; and administrative and consulting services to clinics. The company offers two different options for stem cell regenerative therapy, including autologous adipose derived mesenchymal stem cells and natural killer cells. It also provides coordination services to facilitate its stem cell culturing business, which comprise the introduction of patients to clinics, arranging patients' schedules, and translating between patients and clinics due to language barriers. In addition, Stemcell Holdings, Inc. offers Internet marketing services through search engine optimization for clinics; and property and equipment rental services. The company was formerly known as Perfect Acquisition, Inc., and changed its name to Stemcell Holdings, Inc. in January 2016. Stemcell Holdings, Inc. was founded in 2015 and is based in Tokyo, Japan. as of May 2, 2016, Stemcell Holdings, Inc. operates as a subsidiary of Primavera Singa Pte Ltd.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, underpriced on P/FC.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks